Xencor, Inc. (NASDAQ:XNCR) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $34.00.

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. JPMorgan Chase & Co. boosted their price target on shares of Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. Royal Bank Of Canada upped their price target on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Xencor in a research note on Wednesday, October 21st. Finally, Cantor Fitzgerald increased their price objective on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a report on Thursday, August 6th.

Xencor Stock Performance

NASDAQ:XNCR opened at $25.18 on Wednesday. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -11.60 and a beta of 0.89. Xencor has a 1 year low of $10.38 and a 1 year high of $30.61. The business has a fifty day moving average of $25.37 and a 200-day moving average of $18.43.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%. The company had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. During the same period last year, the company earned ($0.41) earnings per share. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts predict that Xencor will post -3.05 EPS for the current year.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XNCR. Johnson & Johnson bought a new position in Xencor during the 2nd quarter valued at $12,043,798. Hsbc Holdings PLC increased its position in shares of Xencor by 114.2% during the 2nd quarter. Hsbc Holdings PLC now owns 125,482 shares of the biopharmaceutical company’s stock valued at $2,083,000 after purchasing an additional 66,903 shares during the period. Man Group plc bought a new stake in shares of Xencor in the 2nd quarter worth $940,000. Primecap Management Co. CA bought a new stake in shares of Xencor in the 2nd quarter worth $163,919,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Xencor in the 2nd quarter worth $7,828,524,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.